Image source: Getty Images.
What: Shares of Array BioPharma (NASDAQ: ARRY), a cancer-focused clinical-stage biotech, are down more than 22% as of 1:30 p.m. EDT today. The reason is that AstraZeneca (NYSE: AZN) released disappointing late-stage clinical trial results for selumetinib, a compound that it licensed from Array.